Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data

Faden, 2019, How do we select an antipsychotic for those with schizophrenia?, Expert Opin Pharmacother, 20, 2195, 10.1080/14656566.2019.1674284 Howes, 2017, Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology, Am J Psychiatry, 174, 216, 10.1176/appi.ajp.2016.16050503 Taipale, 2021, Comparative effectiveness of antipsychotics for risk of attempted or completed suicide among persons with schizophrenia, Schizophr Bull, 47, 23, 10.1093/schbul/sbaa111 Wagner, 2021, Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review, Transl Psychiatry, 11, 487, 10.1038/s41398-021-01613-2 Lieslehto, 2022, Primary nonadherence to antipsychotic treatment among persons with schizophrenia, Schizophr Bull, 48, 655, 10.1093/schbul/sbac014 Olfson, 2016, Clozapine for schizophrenia: state variation in evidence-based practice, Psychiatr Serv, 67, 152, 10.1176/appi.ps.201500324 Whiskey, 2021, An evaluation of the variation and underuse of clozapine in the United Kingdom, Acta Psychiatr Scand, 143, 339, 10.1111/acps.13280 Farooq, 2019, Barriers to using clozapine in treatment-resistant schizophrenia: systematic review, BJPsych Bull, 43, 8, 10.1192/bjb.2018.67 Pandarakalam, 2019, The art of clozapine therapy and “clozaphobia”, BMJ, 364, 484, 10.1136/bmj.l484 Hiemke, 2018, Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017, Pharmacopsychiatry, 51, 9, 10.1055/s-0043-116492 Siskind, 2021, Clozapine levels as a predictor for therapeutic response: a systematic review and meta-analysis, Acta Psychiatr Scand, 144, 422, 10.1111/acps.13361 Flanagan, 2020, Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals, Br Med Bull, 135, 73, 10.1093/bmb/ldaa024 Pardiñas, 2021, Pharmacogenomics: a road ahead for precision medicine in psychiatry, Neuron, 109, 3914, 10.1016/j.neuron.2021.09.011 Pardiñas, 2019, Pharmacogenomic variants and drug interactions identified through the genetic analysis of clozapine metabolism, Am J Psychiatry, 176, 477, 10.1176/appi.ajp.2019.18050589 Smith, 2020, Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients—a genome-wide association study adjusting for smoking habits, Transl Psychiatry, 10, 198, 10.1038/s41398-020-00888-1 Correll, 2022, A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia, CNS Drugs, 36, 659, 10.1007/s40263-022-00932-2 de Leon, 2022, An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels, Pharmacopsychiatry, 55, 73, 10.1055/a-1625-6388 Williams, 2020, Systematic review of racial disparities in clozapine prescribing, Schizophr Res, 224, 11, 10.1016/j.schres.2020.07.023 Kappel, 2023, Genomic stratification of clozapine prescription patterns using schizophrenia polygenic scores, Biol Psychiatry, 93, 149, 10.1016/j.biopsych.2022.07.014 Brooks, 2017, glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling, R J, 9, 378, 10.32614/RJ-2017-066 Christensen, 2017, Cumulative link models for ordinal regression with the R package ordinal. 2019, R J, 9, 378 Ko, 2022, GWAS of longitudinal trajectories at biobank scale, Am J Hum Genet, 109, 433, 10.1016/j.ajhg.2022.01.018 Millischer, 2022, Improving lithium dose prediction using population pharmacokinetics and pharmacogenomics: a cohort genome-wide association study in Sweden, Lancet Psychiatry, 9, 447, 10.1016/S2215-0366(22)00100-6 Hadfield, 2010, The misuse of BLUP in ecology and evolution, Am Nat, 175, 116, 10.1086/648604 Choi, 2019, PRSice-2: polygenic risk score software for biobank-scale data, Gigascience, 8, 10.1093/gigascience/giz082 Benjamini, 1995, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J R Stat Soc B, 57, 289 McCutcheon, 2018, Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia, Acta Psychiatr Scand, 137, 39, 10.1111/acps.12825 Erickson-Ridout, 2012, Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms, Pharmacogenet Genomics, 22, 561, 10.1097/FPC.0b013e328354026b Eiermann, 1997, The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine, Br J Clin Pharmacol, 44, 439, 10.1046/j.1365-2125.1997.t01-1-00605.x Zhang, 2020, Risk prediction of late-onset Alzheimer's disease implies an oligogenic architecture, Nat Commun, 11